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Abstract
Aim
To develop and test a new tool to assess the avoidability of adverse drug reactions that is
suitable for use in paediatrics but which is also applicable to a variety of other settings.
Methods
The study involved multiple phases. Preliminary work involved using the Hallas scale and a
modification of the existing Hallas scale, to assess two different sets of adverse drug reac-
tion (ADR) case reports. Phase 1 defined, modified and refined a new tool using multidisci-
plinary teams. Phase 2 involved the assessment of 50 ADR case reports from a prospective
study of paediatric inpatients by individual assessors. Phase 3 compared assessments with
the new tool for individuals and groups in comparison to the ‘gold standard’ (the avoidability
outcome set by a panel of senior investigators: an experienced clinical pharmacologist, pae-
diatrician and pharmacist).
Main Outcome Measures
Inter-rater reliability (IRR), measure of disagreement and utilization of avoidability
categories.
Results
Preliminary work—Pilot phase: results for the original Hallas cases were fair and pairwise
kappa scores ranged from 0.21 to 0.36. Results for the modified Hallas cases were poor,
pairwise kappa scores ranged from 0.06 to 0.16.
Phase 1: on initial use of the new tool, agreement between the two multidisciplinary
groups was found on 13/20 cases with a kappa score of 0.29 (95% CI -0.04 to 0.62).
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Phase 2: the assessment of 50 ADR case reports by six individual reviewers yielded pair-
wise kappa scores ranging from poor to good 0.12 to 0.75 and percentage exact agreement
(%EA) ranged from 52–90%.
Phase 3: Percentage exact agreement ranged from 35–70%. Overall, individuals had
better agreement with the ‘gold standard’.
Conclusion
Avoidability assessment is feasible but needs careful attention to methods. The Liverpool
ADR avoidability assessment tool showed mixed IRR. We have developed and validated a
method for assessing the avoidability of ADRs that is transparent, more objective than previ-
ous methods and that can be used by individuals or groups.
Introduction
Adverse drug reactions (ADRs) contribute significantly to patient morbidity, mortality and
hospitalisation costs. ADRs are a major patient safety issue and they can have significant con-
sequences both for the patient and health care system [1]. A recent systematic review of ADRs
in children reported incidences of ADRs in hospitalised children ranging from 0.6 to 16.8%
among studies [2]. This is similar to the incidence rate in hospitalised adults of 14.7% [3]. The
annual cost of drug related morbidity and mortality has been estimated in the United States at
more than $136 billion and ADRs contribute significantly to these costs [4]. Davies et al. esti-
mated that, in the UK, ADRs cost the NHS in excess of £637 million a year; this figure repre-
sents an extrapolation from a single NHS hospital to the NHS as a whole [3]. Children are
considered to be particularly susceptible to ADRs [5,6].
Avoidability (or preventability, as it is also called) is an important concept in the study of
ADRs [7]. The terms are often used interchangeably but for the purpose of this paper, the term
avoidability has been used. A meta-analysis of avoidable ADR studies conducted by Hakkarai-
nen et al. concluded that avoidable ADRs are a significant burden to the healthcare system and
a cause of morbidity among outpatients [8]. They found that roughly half of all ADRs amongst
adult inpatients (45%) and outpatients (52%) may be avoidable [8].
The study of avoidability is complex. A key factor causing this complexity is the lack of
commonly accepted definitions [7]. Hakkarainen et al. listed inconsistent terminology as one
of the problems; there is wide variation in the terms and definitions used (for example ADRs
and adverse drug events (ADEs)) and this hinders the comparison of studies [9]. Ferner and
Aronson [7] stated that there are two aspects to avoidability: whether in principle an event is
avoidable in the absence of error and, if it is, whether we can in fact prevent it. There have
been many attempts to devise tools or scales to help assess avoidability including from Hallas
[10], Schumock and Thornton [11], Dorman et al. [12] and Olivier et al. [13]. The most com-
monly used scales include Hallas [10] and Schumock and Thornton [11], which are based on
appropriateness of prescribing or treatment choice.
In the Adverse Drug Reactions in Children (ADRIC) programme [14], we conducted a
series of studies investigating ADRs including a systematic review, an admissions study and an
inpatient study. The incidence of ADRs detected at the point of admission was 2.9% with the
most commonly implicated drugs being cytotoxics [6]. 17.7% of inpatients experienced at least
one ADR and the most commonly implicated drugs were opioid analgesics and drugs used in
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general anaesthesia [15]. During the ADRIC programme we identified a need to develop a
new ADR causality assessment tool following difficulties using the Naranjo tool. The Liverpool
Causality Assessment Tool (LCAT) is a flow diagram designed by a multidisciplinary team
(MDT) to be quick and easy to use [16]. The assessment of avoidability was central to the
ADRIC study, but during the course of this programme we identified that (a) few previous
studies (19/101) in the ADRIC systematic review had examined avoidability and those that
had, used different methods [2]. The review concluded that the available instruments for the
avoidability assessment of ADRs vary in reliability and validity [2]; and (b) difficulties were
encountered during the assessment of avoidability using existing tools in the ADRIC inpatient
study [15].
The Hallas scale [10] is a series of four statements linked to standards of care. Although the
Hallas scale was used for the ADRIC admissions study, it appeared unsuitable for the ADRIC
inpatient study as the user would need to have comprehensive knowledge of optimal treatment
for all conditions represented in the cohort and the fact that guidelines are incomplete or sim-
ply do not exist. Specifically, Hallas was difficult to use in the inpatient study as treatment was
often guided by tertiary paediatric specialist advice. “Present day knowledge of good medical
practice” of treatments for paediatric diseases covers a vast range of information. Comprehen-
sive awareness of the information required to assess avoidability of ADRs would require exten-
sive reading and synthesis of information. Many paediatric conditions are rare or ultra-rare
which makes information difficult to locate. In contrast, the ADRIC admissions study pre-
dominantly involved a relatively small number of common acute conditions that the research
team were familiar with, or, a relatively small number of acute complications of chronic ill-
nesses that the research team were familiar with. The Hallas scale also had a requirement to
assess whether the event could have been avoided by, “an effort exceeding the obligatory
demands of a case”, which was very difficult to assess consistently and objectively. In view of
these issues, we decided to develop a new avoidability assessment tool. Ideally, a newly devel-
oped tool should be generalisable to a variety of different patient groups, reproducible and
easy to use. The development of the new avoidability assessment tool followed a similar meth-
odology to the development of the LCAT [16]. The aim of this paper is to report the develop-
ment of the tool (termed the Liverpool avoidability assessment tool [LAAT]) and its initial
evaluation.
Methods
Amodified version of the Hallas Scale (Fig 1) was used as the starting point for the develop-
ment of the LAAT. A LAAT development team was convened and included experienced
paediatricians, clinical paediatric pharmacists, a paediatric research nurse and research meth-
odologists. The first principle that the development team agreed on was that the LAAT would
be based on information available in identifiable sources that prescribers would be expected to
use (rather than judgments about best practice). The intention was to keep the tool as generali-
sable as possible by asking if accessible management or treatment plans were available. These
could be local, national or international. We recommended that only high-quality guidelines
were considered. A guideline that is widely available and would be recognised as appropriate
by a reasonable body of opinion for example, in the United Kingdom (UK); Scottish Intercolle-
giate Guidelines Network (SIGN), National Institute for Health and Care Excellence (NICE),
Royal College of Paediatrics and Child Health (RCPCH) or other peer-reviewed guidelines
[17]. Information sources could include the British National Formulary for children (BNF-C),
Summary of Product Characteristics (SmPC) in the UK, or the local equivalent depending on
where the LAAT is being used.
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The second principle was, once the best available management plan had been identified,
that an ADR would be unavoidable if the best available treatment or management plan was fol-
lowed. Thus the steps in the LAAT fell into two types: establishing what the best available
information was and then establishing whether best available information was followed. In all
Fig 1. Hallas and the modified Hallas scale.
doi:10.1371/journal.pone.0169393.g001
Development of the Liverpool ADR Avoidability Assessment Tool
PLOS ONE | DOI:10.1371/journal.pone.0169393 January 3, 2017 4 / 11
phases of this process, assessors were not provided with the relevant guideline and were
expected to apply their awareness and understanding of the current guidelines. The develop-
ment of the LAAT followed the recommendations described by Hakkarainen et al. [9]. They
recommended that future studies include reliability and validity testing; take action to stan-
dardise the measurement process; provide information on the assessors in terms of training
and experience in assessing avoidability; and describe how the assessments took place [9].
Preliminary work–Pilot phase: assessment of modification of an existing
tool
Three reviewers independently assessed 50 cases using a modified version of the Hallas scale
(Fig 1) and 50 cases using the original Hallas scale [10]. The results were compared and inter-
rater reliability (IRR) testing was carried out on both groups using kappa statistics.
It was decided that the LAAT should be converted to a flow diagram in an attempt to make
it easier and more consistent to use. It was also decided that some questions needed reviewing
and that this should be done by a consensus approach. We achieved consensus by agreement
among peers without pre-set criteria and the consensus group was a MDT comprising a
research children’s nurse, paediatrician and pharmacist.
Phase 1: Define the tool
The format of the new tool was a flow diagram with dichotomous responses to each question
followed by a routing to the next relevant question. In Phase 1a, 20 cases were reviewed to
define the tool. This was carried out by an MDT working together to discuss clinical practice
and avoidability outcome and observed by a research pharmacist (Fig 2: The development of
the Liverpool ADR avoidability assessment tool). Any cases which were classified as “unasses-
sable” had the rationale recorded: due to either lack of information about the case or of avail-
able guidance. A clinical pharmacologist, who also reviewed the iterations as they moved
through the various stages of development, reviewed any areas of disagreement or discrepan-
cies. Other steps in Phase 1 are summarised in Fig 2.
Phase 2: Testing and validation of the tool
The refined tool (Fig 3) was then tested on a further set of cases from the ADRIC inpatient
study with the aim being to improve IRR. This phase involved the assessment of a further 50
cases by six individual reviewers using the newly refined tool. See the accompanying glossary
and guide to the questions in the tool for further details on completing an avoidability assess-
ment in S1 Appendix. These 50 cases were a stratified sample (causality assessed as possible,
probable and definite cases: 26 surgical, 9 oncology, 9 medical and 6 cardiology). The reviewers
included two nurses, two pharmacists, and two doctors. These cases were assessed in terms of
pair-wise agreements between the investigators. Avoidability categories ranged from ‘unasses-
sable’, ‘not avoidable’ ‘possibly avoidable’ and definitely avoidable’. As in the development of
the LCAT cases where extreme disagreement occurred, i.e. where the avoidability assessment
differed by more than one category e.g. ‘not avoidable’ and ‘definitely avoidable’ and any cases
where half of the raters differed in assigning a category were identified and the questions
which caused the discrepancies were reviewed [16].
Statistical analysis was carried out using IBM SPSS,Version 22 and StatsDirect Ltd. Stats-
Direct statistical software. http://www.statsdirect.com. The results were presented as categori-
cal scores and inter-rater agreements were calculated using unweighted kappa scores with 95%
confidence intervals (CI). Pair-wise kappa scores were compared to a global kappa score. A
global kappa score measures agreement across multiple assessors [18,19]. The percentage
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extreme disagreement (%ED) where the avoidability scores between two raters of the same
case are wider than one interval apart were calculated to measure extreme disagreement
between pair-wise kappa scores. Pair-wise kappa scores were also calculated by speciality to
investigate the differences between surgical, medical, oncology and cardiology cases. Kappa
values were interpreted according to the guidance from Altman: poor<0.2; fair 0.21–0.4;
moderate 0.41–0.6; good 0.61–0.8 and very good 0.81–1 agreement [18].
Fig 2. Flow chart of the development of the Liverpool ADR avoidability assesmsent tool.
doi:10.1371/journal.pone.0169393.g002
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Phase 3: Consensus methods and individual testing
None of the available formal methods were suitable for our study because the target users of
this tool do not work in large groups. Accordingly we elected to use an informal method that
drew on some elements of the formal methods. The tool was designed for use in real-world
clinical settings. Hence the consensus method chosen should be applicable in real-world set-
tings. The main characteristic of the informal method was small MDT groups. Each group had
3 reviewers including nurse, pharmacist and doctor with experience of prescribing, adminis-
tering, or dispensing medicines for children. It was anticipated that the small groups would
work informally in line with standard practice that does not include formal group processes.
Participants were assigned either to assess a selection of ADR case reports (a purposive sam-
ple of 20 ADR cases, see S1 Table) independently, or to take part in one of the three MDT con-
sensus groups. Nine individual participants (a mixture of nurses, pharmacists and doctors)
independently assessed the selected cases in their own time. Multidisciplinary groups were
formed to assess the cases and reach consensus, during a 3 hour consensus group meeting.
The results were compared to the ‘gold standard’—the avoidability outcome set by a panel of
ADRIC senior investigators (the panel consisted a Clinical Pharmacologist, Paediatrician and
Pharmacist). The extent to which individuals and groups agreed with the ‘gold standard’ using
percentage exact agreement (%EA) was examined.
Fig 3. The Liverpool ADR avoidability assessment tool (LAAT).
doi:10.1371/journal.pone.0169393.g003
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Ethics statement
This study used routinely collected clinical data in an anonymized format. The Chair of the
Liverpool Paediatric Research Ethics Committee informed us that this study did not require
individual patient consent or review by an Ethics Committee. The participants in the study
were all NHS employees who were recruited by virtue of their professional role and therefore
this study did not need NHS REC approval.
Results
Preliminary work–Pilot phase:
The assessment of 50 ADR cases using a modified version of the Hallas scale and a second set
of 50 ADR cases using the original Hallas scale by individuals (a paediatric nurse and two pae-
diatric research pharmacists) [10]. The kappa scores for the Hallas group were fair, with pair-
wise kappa scores ranging from 0.21 to 0.36. The modified Hallas kappa scores were poor,
with pairwise kappa scores ranging from 0.06 to 0.16.
Phase 1
The assessment of 20 ADR cases by two MDTs showed agreement between the groups on 13/
20 cases with a kappa score of 0.29 (95% CI -0.04 to 0.62). Group members commented that a
mixture of professions was needed to give a full assessment of avoidability.
Phase 2
The independent assessment of 50 ADR case reports by six individual reviewers (R1—R6) led
to overall pair-wise kappa scores which ranged from poor to good (0.12 to 0.75). The assessors
achieved fair inter-rater reliability with a global kappa score of 0.31. Overall percentage exact
agreement (%EA) ranged from 52–90% (Table 1) and %ED ranged from 2–24%. Agreement
between specialties varied. Table 2 shows the %EA and %ED between the specialties.
Phase 3
The extent to which individuals and groups agreed with the ’gold standard’ was examined
using %EA. The mean agreement for individuals was 54% (SD 12.4) and 47% (SD 7.6) for the
consensus groups. %EA ranged from 35–70%.
Discussion
We have defined and validated a tool to support the assessment of the avoidability of ADRs
that is based on identifiable information available to the prescriber and an evaluation of
whether the management plan suggested by the best available information was followed. In
addition we have compared the assessments made by groups with the assessments made by
individuals. Agreement with a ‘gold standard’ was similar for individuals and groups. Given
the logistical difficulties with groups, individual assessments can be used in further work. Feed-
back from individuals was generally positive with most participants agreeing that the tool was
easy to use and that it might have potential utility in the future.
Preliminary testing of the LAAT has shown it has face validity and is easy to use. However,
a number of issues were raised. These include the dependence on guidelines and variations in
clinical practice. In phase 2, comparison of reviewers by specialty type highlighted that agree-
ment was better for certain specialties, particularly oncology. This may be explained by the
number of guidelines available in this area as many have detailed protocols and treatment
Development of the Liverpool ADR Avoidability Assessment Tool
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regimens; however, the level of detail varies amongst different protocols. Also, it became
apparent that despite guidelines being available for some cases, not all reviewers chose to look
them up. Some cited guidelines from memory correctly or incorrectly and some clinicians
used experience or prior knowledge to assess the cases. The subtlety in definitions between
prevention, management and amelioration of ADRs caused confusion with reviewers. If the
tool is used by experts then some of these issues may not be relevant.
Avoidability assessment is feasible but needs careful attention to methods. The LAAT
showed mixed IRR when individuals made assessments; further testing was conducted to com-
pare the use of the tool by individuals and groups. One of the limitations was the number of
cases used in some of the development phases. The number of cases was limited due to practi-
cal issues and feasibility. The effect of the small number of cases used is reflected in the wide
confidence intervals for the kappa scores. However, it would not have been possible to have
asked healthcare professionals to assess more ADR cases as conducting avoidability assess-
ments took a considerable amount of time. Also, there was no preset level for kappa acceptabil-
ity for the development of the LAAT. It may have been useful to have assigned a minimum
kappa score for agreement. As the LAAT was designed as a research tool rather than a clinical
tool, the minimum value for kappa might have been set at a lower value than if the LAAT was
designed as a clinical tool. For a clinical tool the minimum kappa score might be set to a mini-
mum of 0.80 which indicates good agreement according to Altman [18] and for the LAAT as a
research it might be more reasonable to set a lower kappa of 0.60 which indicates moderate
agreement. A higher kappa of 0.80 may not be realistic for the LAAT given the complex nature
of avoidability assessments; depending on the expertise of the reviewers conducting the assess-
ments. In any future testing of the LAAT or in re-development of the LAAT into a clinical tool
Table 1. Avoidability assessment of ADR cases from phase 2.
Assessor 2
R1 R2 R3 R4 R5 R6
Assessor 1 R1 % EA 90% 84% 78% 60% 70%
Kappa (95% CI) 0.75 (0.53, 0.97) 0.60 (0.42, 0.79) 0.49 (0.26, 0.72) 0.23 (0.07, 0.38) 0.34 (0.11, 0.56)
R2 % EA 80% 68% 60% 60%
Kappa (95% CI) 0.49 (0.31, 0.67) 0.26 (0.05, 0.46) 0.20 (0.03, 0.37) 0.12 (-0.09, 0.32)
R3 % EA 70% 66% 64%
Kappa (95% CI) 0.30 (0.12, 0.49) 0.32 (0.17, 0.47) 0.21 (0.03, 0.39)
R4 % EA 58% 62%
Kappa (95% CI) 0.23 (0.08, 0.38) 0.20 (-0.02, 0.42)
R5 % EA 52%
Kappa (95% CI) 0.18 (0.03, 0.33)
R6 % EA
Kappa (95% CI)
Kappa values were interpreted according to the guidance from Altman [18].
doi:10.1371/journal.pone.0169393.t001
Table 2. Breakdown of percentage agreement and extreme disagreement between specialties.
Specialty Number of ADR cases %EA Mean Standard deviation %ED Mean Standard deviation
Oncology 9 56–100% 80.2 11.16 0–22.2% 11.1 7.3
Cardiology 6 33–100% 59.0 17.8 0–66.7% 25.5 18.7
Medical 9 33–100% 69.7 20.9 0–22.2% 6.7 7.0
Surgical 26 50–92% 64.5 12.3 3.8–30.1% 19.1 8.8
doi:10.1371/journal.pone.0169393.t002
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for assessing ADRs “a priori” kappa value of 0.6 could be set for the minimum level of agree-
ment for reviewers.
The results from Phase 3 showed that individual assessments had marginally better agree-
ment with the ‘gold standard’ evaluation than group assessments. Qualitative analysis of meet-
ing observations may help identify reasons for this and inform the optimisation of the LAAT
for use in ADR avoidability assessments. The reviewers, particularly in the groups used in
Phase 3 were experienced clinicians with little or no experience with assessment of ADRs. This
pragmatic selection of reviewers may have increased the variability in responses. This could be
investigated in future work to look at the impact of having more experienced group members
assess avoidability and compare inter-rater reliability between the different groups. External
validity testing using expert groups would overcome the lack of understanding about ADRs
and confusion over terminology and is therefore likely to improve the tool’s IRR. In addition,
the provision of training or additional instruction about the use of the tool might help to
improve agreement. A pilot study, randomised controlled trial (RCT) was conducted to test
whether an e-learning tool which was developed to provide training in the use of the Liverpool
causality assessment tool (LCAT) improved the ability of medical trainees to assign ADR cau-
sality using a series of reference ADR cases [20].
Although the LAAT was predominantly designed as a research tool it may have an applica-
tion in other settings. It could potentially be used for organisational change. Inviting members
of the drug and therapeutics committee and senior clinicians with experience in the regulatory
field to assess the avoidability of a selection of ADR case reports using the LAAT, may help to
identify prevention strategies. A thorough exploration of avoidable ADR cases could inform the
development of practical interventions that can be translated into clinical practice. In conclusion
we have developed and validated a method for assessing the avoidability of ADRs that is trans-
parent, more objective than previous methods and that can be used by individuals or groups.
Supporting Information
S1 Appendix. Liverpool ADR avoidability assessment tool glossary.
(DOCX)
S1 Table. Phase 3—Avoidability category assignments of individual reviewers and consen-
sus groups—a comparison to the ‘gold standard’.
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